Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

2.

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB.

JAMA. 1995 Oct 18;274(15):1214-20.

PMID:
7563511
3.

Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.

Martínez-Piñeiro L, Tabernero A, Contreras T, Madero R, Lozano D, López-Tello J, Alonso-Dorrego JM, Picazo ML, González Gancedo P, Martínez-Piñeiro JA, de La Peña JJ.

Eur Urol. 2000 Mar;37(3):289-96.

PMID:
10720854
4.

Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.

Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G.

Cancer. 1997 Nov 1;80(9):1818-29.

PMID:
9351555
5.

Prostate cancer screening in Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur Urol. 1999;35(5-6):523-38.

PMID:
10325519
6.

Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml.

Martínez-Piñeiro L, García Mediero JM, González Gancedo P, Tabernero A, Lozano D, López-Tello JJ, Alonso-Dorrego JM, Núñez C, Picazo ML, Madero R, De La Peña JJ.

World J Urol. 2004 Jun;22(2):124-31. Epub 2004 Feb 20.

PMID:
14986047
8.

Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.

J Urol. 2001 Oct;166(4):1339-42.

PMID:
11547069
10.

Clinical usefulness of free PSA in early detection of prostate cancer.

Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H; Early Detection Project Group of the German Society of Urology.

Onkologie. 2001 Feb;24(1):33-7.

PMID:
11441278
11.

Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.

Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.

Urology. 2003 Apr;61(4):754-9.

PMID:
12670560
12.

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC.

JAMA. 1998 May 20;279(19):1542-7.

PMID:
9605898
13.

Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.

Reissigl A, Klocker H, Pointner J, Fink K, Horninger W, Ennemoser O, Strasser H, Colleselli K, Höltl L, Bartsch G.

Urology. 1996 Dec;48(6A Suppl):62-6.

PMID:
8973702
14.

Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less.

Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ.

J Urol. 1999 Mar;161(3):835-9.

PMID:
10022696
15.
16.

Prostate cancer screening in the Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur J Cancer. 2000 Jun;36(10):1322-35. Retraction in: Eur J Cancer. 2012 Jan;48(2):286.

PMID:
10882875
18.

Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.

Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J.

J Urol. 1998 Mar;159(3):899-903.

PMID:
9474178
19.
20.

Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD.

JAMA. 1997 May 14;277(18):1456-60.

PMID:
9145718

Supplemental Content

Support Center